
uniQure (QURE) Stock Forecast & Price Target
uniQure (QURE) Analyst Ratings
Bulls say
uniQure NV has significantly increased its peak revenue estimates for the gene therapy AMT-130 in Huntington's disease (HD) to approximately $3 billion, driven by its favorable safety profile and sustained efficacy. The company's commercial infrastructure is strategically positioned to support a robust launch in 2026, enhancing its prospects for rapid physician adoption and solid engagement with advocacy networks. Furthermore, the absence of approved disease-modifying treatments for HD presents a substantial market opportunity, aligning with the high unmet needs within this patient population.
Bears say
uniQure NV is facing significant challenges due to delays in the regulatory approval process for its AMT-130 gene therapy, leading to a reduction in the probability of success from 65% to 55%. Additionally, the company operates without any revenue-generating products and has consistently reported losses since its inception, highlighting its precarious financial position as a clinical-stage entity. Furthermore, the competitive landscape for gene therapies targeting similar indications presents risks to market penetration and pricing, further complicating uniQure's outlook in the evolving gene therapy market.
This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.
uniQure (QURE) Analyst Forecast & Price Prediction
Start investing in uniQure (QURE)
Order type
Buy in
Order amount
Est. shares
0 shares